BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Female Health Company Names Karen King President And Chief Executive Officer


12/11/2013 10:50:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, Dec. 11, 2013 /PRNewswire/ -- Today The Female Health Company (NASDAQ-CM: FHCO), announced that Karen King will become President and CEO effective January 20, 2014. O.B. Parrish, a Company founder and current Chairman and CEO will continue as Chairman of the Board.

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Karen King was President of the Biologics and BioSolutions businesses at Royal DSM from 2007 to 2013. DSM Biologics/BioSolutions is a global provider of biopharmaceutical manufacturing technology and services.

Previously Ms. King was an executive officer of the Female Health Company from 2004 2006, serving most recently as Executive Vice President where she was responsible for sales, marketing and business development.

Prior to joining FHC, Ms. King had an extensive career with Baxter International beginning in 1981. During her Baxter tenure, Ms. King held positions in R&D, Operations, Marketing, Business Development, Corporate Strategy, Innovation and General Management. She was Executive Director of Baxter's Collaboration with Inhale Therapeutics focusing on the development and commercialization of a novel technology for respiratory drug delivery. In her final position at Baxter, Ms. King was the President of Pulse Nutrition Solutions, Inc from 2000 2003. Pulse Nutrition Solutions was a subsidiary of Baxter devoted to developing and commercializing a line of nutritional products for consumer use.

Ms. King is a graduate of the University of Illinois with a Bachelor of Science degree in Microbiology.

O.B. Parrish said "I am delighted to have Karen join FHC as President and CEO. She has a remarkable combination of successful global experience including marketing, technology, science and business development in both the private and public sectors. Karen's prior experience with FHC equips her with significant relevant knowledge of the Company's history and development, as well as its potential. This change in leadership comes at a time when the Company's future is bright. Karen will provide excellent leadership for the further development and growth of FHC."

Karen King said, "I am honored to be rejoining FHC in this capacity. O.B. and his team have done a wonderful job building a strong, successful company. I am looking forward to working with O.B. and FHC's customers, employees and shareholders to continue the important work of the company and position it for future growth and success."

About the Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 143 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com

SOURCE The Female Health Company



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES